Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595349 | 1.00 | CYP3A4 (0.51) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL3592585 | 0.83 | CA12 (0.48) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL3592587 | 0.83 | CA12 (0.48) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL19661458 | 0.80 | LMNA (0.57) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL15203065 | 0.80 | LMNA (0.57) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL1273122 | 0.80 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL5948337 | 0.78 | CYP3A4 (0.67) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL27653496 | 0.78 | CYP3A4 (0.50) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL2314314 | 0.76 | SLC6A2 (0.48) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL | |
| SCHEMBL28806779 | 0.76 | SLC6A2 (0.48) | CYP3A4ALDH1A1CYP2C9CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394837-B2 | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1817311-B1 | 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1740581-B1 | 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1689713-A4 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK & CO INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-01-17 | — | — | US | disclosed |
| US-20070293497-A1 | 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| CN-1882544-A | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer s disease | MERCK & CO INC (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1689713-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051914-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293497-A1 | 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease | BACE1, BACE2, PSEN2 | CYP3A4 507/4885ALDH1A1 1968/4885CYP2C9 1303/4885 |
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN2 | CYP3A4 429/4885ALDH1A1 2019/4885CYP2C9 1624/4885 |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | BACE1, BACE2, APP | CYP3A4 1143/4885ALDH1A1 1760/4885CYP2C9 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.